{"id":89269,"date":"2026-05-12T22:26:57","date_gmt":"2026-05-13T04:26:57","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=89269"},"modified":"2026-05-13T16:46:16","modified_gmt":"2026-05-13T22:46:16","slug":"compounded-glp-1-during-shortage","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/compounded-glp-1-during-shortage\/","title":{"rendered":"Compounded GLP-1 During Shortage: Is It Still Available"},"content":{"rendered":"

Introduction<\/h2>\n

The compounded GLP-1 market exploded between 2022 and 2024 when both semaglutide and tirzepatide sat on the FDA shortage list. Section 503B outsourcing facilities legally produced brand-equivalent compounded versions, and demand poured in. That window closed in December 2024 for tirzepatide and May 2025 for semaglutide.<\/p>\n

The question in 2026 isn’t whether compounded GLP-1 is legal. It’s under what conditions. This piece walks through what changed, what’s still available, and how to tell a legitimate compounding pharmacy from a sketchy one.<\/p>\n

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n

Is Compounded GLP-1 Legal in 2026?<\/h2>\n

Yes, but in a narrower way than during the shortage period.<\/strong> Federal law allows two types of compounding pharmacies: section 503A pharmacies, which are state-licensed and compound for individual patients with prescriptions, and section 503B outsourcing facilities, which are FDA-registered and can compound at larger scale.<\/p>\n

Quick Answer: The FDA’s 503B mass-compounding exception ended December 2024 for tirzepatide and May 2025 for semaglutide<\/p>\n

503B facilities lost the legal basis to mass-produce brand-equivalent semaglutide and tirzepatide once those drugs came off the FDA shortage list. 503A pharmacies retain the ability to compound on a patient-specific basis when the prescriber documents a clinical reason commercial product won’t work.<\/p>\n

State pharmacy boards have stepped up enforcement against pharmacies that ignore the clinical-justification requirement, and the FDA has issued warning letters to several telehealth operations that prescribed compounded GLP-1 without meaningful clinical screening.<\/p>\n

What Clinical Reasons Justify Compounded GLP-1?<\/h2>\n

The most common are allergies to inactive ingredients in commercial Wegovy\u00ae or Zepbound\u00ae formulations.<\/strong> Both contain preservatives and stabilizers that some patients can’t tolerate. A documented allergy or significant adverse reaction supports compounding without those agents.<\/p>\n

The second is non-standard dose strengths. Commercial Wegovy comes in 0.25, 0.5, 1.0, 1.7, and 2.4 mg pens. Commercial Zepbound comes in 2.5 through 15 mg in 2.5 mg increments. Patients who need a specific intermediate dose for clinical reasons (titration sensitivity, slow GI tolerance) may have a case for compounded micro-doses.<\/p>\n

The third is combination products. Semaglutide compounded with B-12 or other agents is a legitimate clinical indication when the prescriber documents the reason. Off-label combination weight-loss stacks without clinical rationale generally aren’t acceptable.<\/p>\n

Simply being unable to fill a commercial prescription is not, by itself, sufficient under most state board interpretations.<\/p>\n

What Changed After the FDA Shortage Declaration?<\/h2>\n

For tirzepatide, the December 19, 2024 declaration ended the 503B exception.<\/strong> Several large outsourcing facilities that had been producing compounded tirzepatide stopped or pivoted to other products. For semaglutide, the February 21, 2025 declaration ended the 503B exception for that molecule. The 60-day grace period to wind down ended May 22, 2025.<\/p>\n

After those dates, 503B production of brand-equivalent GLP-1 was no longer legal. 503A patient-specific compounding continued under the higher clinical-justification standard.<\/p>\n

A small number of 503B facilities sued the FDA challenging the shortage declarations and the speed of the wind-down. Most lawsuits failed. The legal picture has settled by 2026.<\/p>\n

How Do I Tell a Legitimate Compounding Pharmacy From a Sketchy One?<\/h2>\n

Three signals. First, the pharmacy should be licensed in your state and able to provide a state license number on request. Look it up on your state pharmacy board’s website. Legitimate 503A pharmacies are happy to share.<\/p>\n

Second, the prescribing telehealth platform should do a real clinical assessment, not a 60-second form. A licensed prescriber should review your medical history, current medications, and clinical indication before writing a prescription. If the process feels like ordering a sandwich, that’s a red flag.<\/p>\n

Third, the pharmacy should disclose which active pharmaceutical ingredient (API) source it uses and provide certificates of analysis on request. Reputable compounders use FDA-registered API suppliers and can document purity and identity testing.<\/p>\n

TrimRx works only with pharmacies that meet all three criteria. The free assessment quiz is a real medical screening, not a checkbox formality.<\/p>\n

Are 503B Facilities Still Making Any GLP-1 Products?<\/h2>\n

A small number of 503B facilities continue producing compounded semaglutide and tirzepatide in combination or non-standard formulations that don’t replicate the commercial brand product.<\/strong> Those formulations need to be meaningfully different from FDA-approved drugs to fall outside the resolved-shortage restriction.<\/p>\n

For example, semaglutide-B-12 combination injections in specific concentrations remain available through some 503B facilities. Whether these are clinically necessary or just a workaround is debated. The FDA has signaled it will look closely at combination products to ensure they aren’t just cover for brand replication.<\/p>\n

For most patients, the relevant supply is 503A patient-specific compounding through state-licensed pharmacies.<\/p>\n

Key Takeaway: Acceptable reasons include allergies to inactive ingredients, non-standard dose needs, or combination products<\/p>\n

What Does Personalized Compounded GLP-1 Cost?<\/h2>\n

Pricing varies by pharmacy, dose, and quantity.<\/strong> In 2026, monthly costs for personalized compounded semaglutide typically range $200 to $400. Tirzepatide compounds typically run $300 to $500 per month at common doses.<\/p>\n

Brand-name Wegovy retail prices run $1,000+ per month without insurance, or $499 through NovoCare direct. Brand-name Zepbound retail is similar, with LillyDirect Self-Pay vials at $349 to $499 per month.<\/p>\n

Compounded therapy is usually not covered by insurance. The cash price difference versus brand can be meaningful, especially for uninsured patients or patients whose insurance denies obesity coverage.<\/p>\n

Is Compounded GLP-1 as Effective as Brand?<\/h2>\n

The active ingredient is the same molecule when compounded from FDA-registered API.<\/strong> Bioequivalence studies of compounded semaglutide and tirzepatide against brand are limited because compounded products don’t go through the FDA-approved bioequivalence pathway used for generics.<\/p>\n

In practice, patient-reported outcomes on compounded GLP-1 are broadly similar to brand outcomes when the product is sourced from a quality compounder. Patients who switched from brand to compound during the 2022 to 2024 shortage generally maintained their results.<\/p>\n

The variability is higher than with brand-name products because compound batches differ across pharmacies. That’s why pharmacy selection matters more for compounded than for brand-name therapy.<\/p>\n

What Should I Ask Before Starting Compounded GLP-1?<\/h2>\n

Ask the prescribing platform whether the prescriber is licensed in your state, whether you’ll have access to that prescriber for follow-up questions, and what the dose titration plan looks like.<\/strong> Real medical care includes ongoing monitoring, not just a one-time prescription.<\/p>\n

Ask the pharmacy where the API is sourced, whether each batch is tested for identity and purity, and whether you can request certificates of analysis. Legitimate compounders test every batch and document.<\/p>\n

Ask about cold chain shipping. Semaglutide and tirzepatide require refrigeration. Pharmacies that ship from controlled-temperature warehouses with cold-pack packaging are doing it right. Pharmacies that ship room-temperature are cutting corners.<\/p>\n

What If I Was on Compounded GLP-1 Before the FDA Changes?<\/h2>\n

Many patients were on 503B-produced compounded semaglutide or tirzepatide before December 2024 or May 2025.<\/strong> After the deadlines, prescriptions through 503B couldn’t be refilled, and patients had to transition.<\/p>\n

Options were: switch to brand Wegovy or Zepbound, transition to a 503A patient-specific compound with documented clinical justification, or switch to a different drug class. Most patients found a path. Some did pause therapy for weeks while figuring it out.<\/p>\n

In 2026, the patients still on compounded GLP-1 are those with documented clinical reasons that satisfy 503A standards or those using combination products.<\/p>\n

Bottom line: Online “telehealth + compounding” operations that bypass clinical justification have faced FDA warning letters<\/p>\n

FAQ<\/h2>\n

Did the FDA Ban Compounded Semaglutide and Tirzepatide?<\/h3>\n

No. The FDA ended the 503B mass-production exception. 503A patient-specific compounding continues under existing rules.<\/p>\n

Is Compounded GLP-1 Safe?<\/h3>\n

When sourced from a reputable state-licensed 503A pharmacy that tests each batch, yes. When sourced from offshore websites or unlicensed compounders, no, the risks include contamination, wrong concentration, and counterfeit API.<\/p>\n

Can My Regular Doctor Prescribe Compounded GLP-1?<\/h3>\n

Yes, any licensed prescriber can write a prescription for a compounded medication when there’s a documented clinical reason. Most primary care doctors don’t because they’re unfamiliar with the workflow.<\/p>\n

How Does TrimRx Handle the FDA Changes?<\/h3>\n

TrimRx works with state-licensed 503A pharmacies and screens for clinical justification through a real medical assessment. The free assessment quiz is the start of that process.<\/p>\n

Can I Get Compounded GLP-1 Cheaper Online?<\/h3>\n

Some online operations price below $200 per month. Many of those cut corners on API sourcing, testing, or clinical screening. Cheap isn’t always safe.<\/p>\n

Will the FDA Allow 503B Compounding Again?<\/h3>\n

Only if a new shortage is declared. Absent that, the 503B exception remains closed for brand-equivalent GLP-1 products.<\/p>\n

Does Insurance Ever Cover Compounded GLP-1?<\/h3>\n

Rarely. Some plans cover compounded medications when there’s a documented medical necessity that brand product can’t address, but blanket coverage doesn’t exist. Most patients pay cash.<\/p>\n

Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n

<\/p>\n

Related Articles<\/h2>\n